[go: up one dir, main page]

CL2018000914A1 - Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular - Google Patents

Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular

Info

Publication number
CL2018000914A1
CL2018000914A1 CL2018000914A CL2018000914A CL2018000914A1 CL 2018000914 A1 CL2018000914 A1 CL 2018000914A1 CL 2018000914 A CL2018000914 A CL 2018000914A CL 2018000914 A CL2018000914 A CL 2018000914A CL 2018000914 A1 CL2018000914 A1 CL 2018000914A1
Authority
CL
Chile
Prior art keywords
gaba
psicologicos
neurologicos
inactivadores
hepatocelular
Prior art date
Application number
CL2018000914A
Other languages
English (en)
Inventor
Richard B Silverman
Kenji Takaya
Hoang V Le
Jose I Juncosa
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of CL2018000914A1 publication Critical patent/CL2018000914A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos relacionados con el ciclopenteno del ácido carboxílico como inhibidores GABA-AT para el tratamiento de diversas adicciones, trastornos y estados patológicos.
CL2018000914A 2015-10-09 2018-04-09 Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular CL2018000914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562239330P 2015-10-09 2015-10-09

Publications (1)

Publication Number Publication Date
CL2018000914A1 true CL2018000914A1 (es) 2018-08-31

Family

ID=58488679

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000914A CL2018000914A1 (es) 2015-10-09 2018-04-09 Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular

Country Status (20)

Country Link
US (3) US9670141B2 (es)
EP (1) EP3341355B1 (es)
JP (1) JP6841821B2 (es)
KR (1) KR102745965B1 (es)
CN (1) CN108137484B (es)
AU (1) AU2016334396B2 (es)
BR (1) BR112018007026B1 (es)
CA (1) CA3001330A1 (es)
CL (1) CL2018000914A1 (es)
CO (1) CO2018003828A2 (es)
DK (1) DK3341355T3 (es)
ES (1) ES2825349T3 (es)
HU (1) HUE053429T2 (es)
IL (1) IL258516A (es)
LT (1) LT3341355T (es)
MX (1) MX380592B (es)
PE (1) PE20190349A1 (es)
PL (1) PL3341355T3 (es)
PT (1) PT3341355T (es)
WO (1) WO2017062942A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3183254T (pt) 2014-08-21 2019-08-29 Boehringer Ingelheim Int Novos compostos de espiro[3h-indole-3,2¿-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53
PL3341355T3 (pl) * 2015-10-09 2021-03-08 Northwestern University Kwas (S)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowy i związki pokrewne jako dezaktywatory aminotransferazy GABA do leczenia padaczki, uzależnienia oraz raka wątrobowokomórkowego
SI3359542T1 (sl) 2015-10-09 2021-08-31 Boehringer Ingelheim International Gmbh Spojine in derivati spiro(3H-indol-3,2'-pirolidin)-2(1H)-ona kot MDM2-P53 inhibitorji
KR20240110989A (ko) 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들
US10653652B2 (en) 2018-02-08 2020-05-19 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
US11771671B2 (en) * 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
CN112218628A (zh) * 2018-03-29 2021-01-12 奥维德医疗公司 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途
US10822301B2 (en) 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
US10836708B2 (en) * 2018-05-25 2020-11-17 Northwestern University Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid
JP7387179B2 (ja) 2018-06-07 2023-11-28 オービッド・セラピューティクス・インコーポレイテッド 発達障害の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸および関連化合物、（１ｓ，３ｓ）－３－アミノ－４－（ジフルオロメチリデン）シクロペンタン－１－カルボン酸ならびにビガバトリンの使用
WO2020176511A1 (en) 2019-02-25 2020-09-03 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene) cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
WO2020206234A1 (en) 2019-04-03 2020-10-08 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
CN110935495B (zh) * 2019-11-29 2021-02-23 中国科学院电子学研究所 Gaba和电生理微纳同步传感检测芯片及其制备方法
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
CN117321025A (zh) * 2021-03-03 2023-12-29 西北大学 作为人鸟氨酸氨基转移酶的选择性灭活剂的(s)-3-氨基-4,4-二卤代环戊-1-烯甲酸
EP4551205A4 (en) * 2022-07-06 2025-11-12 Ovid Therapeutics Inc USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN CANCER TREATMENT
KR20250149771A (ko) * 2023-02-17 2025-10-16 오비드 테라퓨틱스 인크. 위장관 장애의 치료 및 면역조절제로서의 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
KR20250145688A (ko) * 2023-02-17 2025-10-13 오비드 테라퓨틱스 인크. 당뇨병 및 당뇨 전단계의 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
US20240285563A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis
AU2024220869A1 (en) * 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
IL177609A (en) 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma
EP2542234A4 (en) * 2010-02-25 2013-07-31 Univ Northwestern PROCESS FOR USE OF (1S, 3S -) - 3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANIC ACID
AR087700A1 (es) * 2011-08-30 2014-04-09 Gilead Sciences Inc Inhibidores de aldh-2 en el tratamiento de adicciones
PL3341355T3 (pl) * 2015-10-09 2021-03-08 Northwestern University Kwas (S)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowy i związki pokrewne jako dezaktywatory aminotransferazy GABA do leczenia padaczki, uzależnienia oraz raka wątrobowokomórkowego

Also Published As

Publication number Publication date
US20170239202A1 (en) 2017-08-24
CN108137484B (zh) 2021-02-12
US9993449B2 (en) 2018-06-12
PL3341355T3 (pl) 2021-03-08
CN108137484A (zh) 2018-06-08
HUE053429T2 (hu) 2021-07-28
AU2016334396A1 (en) 2018-04-19
IL258516A (en) 2018-05-31
US20180271816A1 (en) 2018-09-27
US9670141B2 (en) 2017-06-06
BR112018007026A2 (pt) 2018-10-16
WO2017062942A3 (en) 2018-03-01
BR112018007026B1 (pt) 2022-06-21
AU2016334396B2 (en) 2021-04-08
MX380592B (es) 2025-03-12
US20170101364A1 (en) 2017-04-13
PE20190349A1 (es) 2019-03-07
EP3341355A2 (en) 2018-07-04
HK1253002A1 (zh) 2019-06-06
PT3341355T (pt) 2020-10-21
LT3341355T (lt) 2020-11-10
KR102745965B1 (ko) 2024-12-20
EP3341355A4 (en) 2019-04-10
CA3001330A1 (en) 2017-04-13
CO2018003828A2 (es) 2018-07-19
ES2825349T3 (es) 2021-05-17
EP3341355B1 (en) 2020-09-30
JP6841821B2 (ja) 2021-03-10
JP2018531941A (ja) 2018-11-01
KR20180052782A (ko) 2018-05-18
WO2017062942A2 (en) 2017-04-13
DK3341355T3 (da) 2020-10-26
MX2018004302A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
CL2018000914A1 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
NI201600056A (es) Inhibidores de bromodominio
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
HUE059559T2 (hu) 5HT agonisták az epilepsziás rendellenességek kezelésére
BR112017006664A2 (pt) terapias de combinação
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
EA201892008A1 (ru) Соединения и способы лечения неврологических и сердечно-сосудистых состояний
UY33910A (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC
PL3157534T3 (pl) Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX375438B (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
BR112017009289A2 (pt) métodos de administrar composições de amantadina
UY34719A (es) Proceso para la producción de inhibidores de crr
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
LT3322438T (lt) Il-8 inhibitoriai, skirti naudoti tam tikrų urologinių susirgimų gydymui
MX2019006143A (es) Metodos de administracion de tratamiento antifibrotico.